COMPANY PROFILE

BioProtect

Explore full profile

Protecting Healthy Tissue in Radiation Oncology

Kochav Yair, IsraelFounded 2004Biotech & Life Sciences

Valuation $100–250M Last recorded · 2023

Headcount 100–500 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About BioProtect

Developer of a pro-space balloon system designed to safely and temporarily separate the rectum from the prostate during prostate cancer radiation therapy. The company's system acts as a spacer for the protection of healthy tissues in patients receiving radiotherapy for prostate cancer, enabling healthcare institutions to dramatically decrease the probability of serious and chronic radiation side effects while improving biochemical tumor control.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2004
Headquarters: Kochav Yair, Israel
Employees: 120
Open positions: 9
Dealroom signal: 90.8/100
Industry: Health
Sub-industry: BioTechnology, Medical Devices
Sector: Biotech & Life Sciences, Biotechnology, Oncology, EIC, Biotech and Pharma, Hard Tech, Horizon Europe, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	Jan 2026	$200M	$200M	Undisclosed	↗
LATE VCOther financing	Sep 2023	$28M	$112M	TriVentures · Almeda Ventures · MVM Life Science Partners · Peregrine Ventures	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

BioProtect website traffic

Latest recorded traffic for BioProtect is 340 monthly website visits, down 52.8% over the last three months. BioProtect's team grew 11.1% over the past year.

Latest monthly visits340 3-month web change-52.8% 1-year team growth+11.1%

Monthly website visitsJun 2015–Apr 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Production PlannerNetanya, Center District, Israel · Project Management · Sep 6, 2026 Validation EngineerNetanya, Israel, Western Asia, Asia · Other · Aug 13, 2026 Research And Development EngineerNetanya, Center District, Israel · Other · Jul 29, 2026 R&D EngineerTsur, Zur Yigal, Kochav Yair, Petah Tikva Subdistrict, Center District, Israel · Other · Jul 21, 2026 QA Operations Team LeadNetanya, Center District, Israel · Business Intelligence · Jun 11, 2026

5 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NPNovo PathDeveloped an extracorporeal device to effectively and specifically extract plasma proteins responsible for hyperfibrinolysis	Nazareth, Israel	Operational	60	$2.3M	—
NTNEOGAP TherapeuticsImagine if cancer patients who lack efficient treatment options could be cured	Stockholms kommun, Sweden	Operational
CTCeleris TherapeuticsPredicting biomolecular interactions and designing drugs for incurable diseases	Graz, Austria	Operational
PTPROSION TherapeuticsPROSION Therapeutics is a drug development company with a proprietary platform that addresses highly unmet medical needs by unlocking undruggables	Cologne, Germany	Operational
ATAsgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming	Lund Municipality, Sweden	Operational
NTNectin TherapeuticsA Startup dedicated to the development of next generation immuno-oncology antibodies	Jerusalem, Israel	Operational
APAbility PharmaAbilityPharma is a clinical stage phase 2b biopharmaceutical company focused on autophagy to treat cancer	Cerdanyola del Vallès, Spain	Operational
MUMultiplexDXEliminating cancer misdiagnosis by launching a new diagnostic test in 2023 and operating a boutique oligo house	Rockville, United States	Operational